|
|
||||||||



*
Laboratoire dImmunologie Cellulaire, Unité Mixte de Recherche 7627, Centre National de la Recherche Scientifique, Hôpital Pitié-Salpêtrière, Paris, France;
Unité Mixte de Recherche, Centre National de la Recherche Scientifique 144, Institut Curie, Paris, France; and
Laboratoire dImmunologie Cellulaire de lÉcole Pratique des Hautes Études, Hôpital Pitié-Salpêtrière, Paris, France
| Abstract |
|---|
|
|
|---|
accelerated the differentiation of progenitors into DC
and augmented MHC class II transport to the membrane, resulting in
improved capacity to induce MLR. The trafficking of MHC class II
molecules was studied by metabolic labeling and immunoprecipitation.
MHC class II molecules were transported to the membrane in association
with invariant chain isoforms in CD14+ (monocyte)-derived
and in CD1a+ thymic-derived DC but not in monocytes. Thus,
thymic progenitors can differentiate into DC along a preferential
CD1a+ pathway but have conserved a CD14+
maturation capacity under M-CSF. Finally, CD1a+-derived
thymic DC and monocyte-derived DC share very close Ag-processing
machinery. | Introduction |
|---|
|
|
|---|
DC in humans can arise both from CD34+ bone marrow
progenitors under GM-CSF + TNF-
(7, 8) and from peripheral blood
monocytes under GM-CSF + IL-4 (2). DC were generally considered to
belong to the myeloid lineage because they arise from monocytes (2).
The fact that CD34+ cord blood progenitors cultured in
GM-CSF + TNF-
lead independently to cells expressing
CD14+, a marker of monocytes, and to
CD14-CD1a+ precursor cells indicated the
existence of two independent pathways for the generation of DC (8).
Thymic DC do not behave only as classical APC and appear to have
distinct biological properties compared with DC in other tissues.
Although they can be as good as peripheral DC in stimulating allogeneic
T cells (9), their role in vivo is to determine clonal deletion
(negative selection) of autoreactive thymocytes, thereby inducing
central tolerance as demonstrated in murine models (10, 11). Human
thymic DC have generally been regarded as lymphoid because they arise
from CD34+ progenitors with little if any myeloid
differentiation potential and because they express lymphoid surface
markers such as CD2, CD5, and CD7 (6, 12). The existence of oligopotent
progenitors in the fetal liver and the bone marrow with lymphoid but no
myeloid maturation capacity and a phenotype matching that of thymic
precursors suggests that they migrate to seed the thymus (13, 14). The
existence of a common T lymphocyte/DC progenitor (5) or of a common
NK/dendritic precursor in the human or mouse thymus was demonstrated
(15) or indirectly suggested (16), further supporting the general view
that thymic DC arise from an independent lymphoid-committed lineage.
Although data concerning human thymic DC are rather sparse, cells
isolated in vivo or cultured from precursors have not been reported to
express typical surface lymphoid markers (6, 17) contrary to murine DC
which express CD8
(2, 5, 11, 18). The recently reported NK/DC
precursor in the human thymus is CD33low (15), whereas most
CD34+ thymic precursors are CD33 negative (19). This subset
was reported to mature into DC with a
CD13+CD33high phenotype closer to the myeloid
than to the lymphoid lineage (15). Altogether, thymic DC may
express either lymphoid or myeloid markers or both. Therefore, the
reasons to classify thymic DC as "lymphoid" rely on their ontogeny
rather than on their phenotype. The growth/maturation factors for
thymic DC have also been questioned. Although GM-CSF seems central in
most studies of DC generation from monocytes and bone marrow
progenitors, one study in mice (18) and another in humans (20) shows
that it is dispensable. Indeed, human
CD34+CD44intermediate thymic precursors
cultured in IL-7 generated DC and CD14+ cells. In our
previous work aimed at determining the myeloid capacity of thymic
progenitors, several conditions were tested, but we did not add
macrophage CSF (M-CSF) to the cultures (19). Since M-CSF is known to
support the survival of monocytes and the proliferation of their
precursors (21), we studied its effects on thymic precursors.
The present study was undertaken to evaluate the growth factors needed
for the generation of DC from thymic progenitors with a particular
focus on GM-CSF, M-CSF, and TNF-
. We also investigated whether
thymic DC differentiated along the same CD1a+- or
CD14+-derived pathways already evidenced in cord blood (8).
The effect of TNF-
on thymic DC was investigated and was shown to be
acceleration of the differentiation of DC from progenitors as well as
the activation of DC. Activation was evidenced by the improved capacity
of DC to induce allogeneic MLR and to express high MHC class II levels
at the plasma membrane as shown by confocal microscopy. The capacity of
cells to present Ags is conditioned by their level of class II molecule
synthesis and by intracellular trafficking of class II and invariant
chains (22, 23). This led us to investigate whether thymic DC were
different from monocyte-derived DC in this respect. Metabolic labeling
and immunoprecipitation of class II/Ii chain complexes were thus
performed in cultured cells from both lineages.
Altogether we present evidence that thymic DC-differentiating capacity, albeit much lower than that of cord blood, took place along the same pathways. In addition, thymic DC were very similar to monocyte-derived DC regarding their expression and trafficking of MHC class II and their ability to induce allogeneic MLR.
| Materials and Methods |
|---|
|
|
|---|
Flow cytometric studies were performed with control mouse-Ig-FITC or MSIg-PE, CD1a (T6-PE/), CD2 (T11-FITC), CD3 (T3-FITC), CD4 (T4-FITC), CD5 (T1-PE), CD7 (3A1-PE), CD8 (T8-PE), CD10 (J5-FITC), CD14 (My4-FITC), CD33 (My9-PE), CD45RA (2H4-FITC), CD56 (NKH1-PE), CD116 (SCO6-PE), CD40 (MAB89-PE), CD11-b (Bear1-FITC), and CD83 (HB15a-PE), all from Coulter-Immunotech, Marseille, France; anti-HLA-DR-FITC (1243/class II), CD4-PE (Leu-3a), CD34 (HPCA-2-FITC), and CD38 (Leu-17-PE), all from Becton Dickinson, Mountain View, CA; CD115 (c-fms, Santa Cruz Biotech, Santa Cruz, CA); CD80 (mAb 104-FITC), CD86 (FUN/B7.2, PharMingen, San Diego, CA), and E-cadherin (HECD-1, Takara Shuzo, Japan); and CD1a-FITC (Dako, Copenhagen, Denmark).
Purification of thymic cell subpopulations
Populations were obtained as previously described (19). Normal thymuses were obtained from children undergoing corrective cardiac surgery. Samples were minced in cold HBSS with 2% FCS and 1% penicillin/streptomycin (HFA medium). Thymocytes were isolated by Ficoll gradient density centrifugation. Cells at the interface were washed with HFA, and sequential depletion in CD3-, CD4-, CD8-, and CD19-expressing cells was performed in HFA using mAb-coated beads (Dynal Biosys, Compiègne, France). To this end, cells (20 x 106/ml) were incubated with UCHT1 CD3 mAb for 30 min at 4°C, washed, and incubated with sheep anti-mouse IgG-coated magnetic beads for 30 min at 4°C, at 2 beads/cell. After magnetic depletion, uncoated cells were resuspended with beads coated with CD4, CD8, and CD19 mAb at the above bead/cell ratio. When needed, an anti-glycophorin A mAb (JC159, Dako) was added to deplete residual RBC. Cells were thereafter stained with 20 µl/107 cells of CD34-FITC (HPCA-2 mAb) and 5 µl/107 cells of CD1a (T6) mAb for 45 min at 4°C. After washing, cells resuspended in HFA were sorted with the FACStarPlus equipped with an argon laser emitting at 488 nm. Cells were kept at 4°C during the sorting procedure.
Immunofluorescence and confocal microscopy
DC were allowed to adhere for 30 min at 37°C on glass coverslips precoated with a 0.1% poly-L-lysine in water. Cells were fixed in 3% paraformaldehyde for 10 min at room temperature and permeabilized with 0.05% saponin in PBS supplemented with 0.2% BSA. Cells were stained with anti-MHC class II (HLA-DRab dimer) and either CD1a or CD63 mAbs. Cells were first incubated with BL6 Ab (IgG1 CD1a, Immunotech, Marseille, France) for 30 min, washed three times, and incubated with Texas red-conjugated secondary Abs (Jackson Immunoresearch Laboratories, West Grove, PA). Alternatively, cells were incubated with cyanine 3-conjugated H5C6 Abs (IgG1 anti-CD63, provided by Dr. F. Lanza, Establissement Transfusion Sanguine, Strasbourg, France). Conjugation was performed using the Cy3 monoreactive dye pack (Amersham, Les Ulis, France). For double staining, cells were incubated with FITC-conjugated L243 (IgG2a, Becton Dickinson) conjugated in our laboratory using FLUOS (Boehringer Mannheim, Mannheim, Germany). Coverslips were then mounted in Mowiol (Sigma Aldrich, Lisle dAbeau, France).
Confocal laser scanning microscopy and immunofluorescence analysis were performed with a TCS4D confocal microscope based on a dichroic mirror microscope interfaced with an argon/krypton laser. Simultaneous double-fluorescence acquisitions were performed using the 488 nm and the 568 nm laser lines to excite FITC and Texas red dyes using a 100x oil immersion plan Apo objective (numerical aperture, 1.4). The fluorescence was selected with the appropriate double-fluorescence dichroic mirrors and band pass filters and measured with blue-green sensitive and red side-sensitive-one photomultipliers. The images shown correspond to the merging of four confocal microscopy slices.
Liquid cultures and cytokines for thymic and monocyte-derived DC
The following final concentrations of factors were used: stem
cell factor (SCF) (50 ng/ml) and IL-7 (20 ng/ml), both from Valbiotech
(Paris, France); flt3L (50 ng/ml), IL-3 (10 ng/ml), GM-CSF (10 ng/ml),
TNF-
(10 U/ml), and IL-4 (200 U/ml), all from Genzyme (Cambridge,
MA); and M-CSF (20 ng/ml) from R&D Systems (Minneapolis, MN). Sorted
CD34+CD1a- or
CD34+CD1a+ thymocytes were cultured at
106/ml in RPMI supplemented with 2 mM glutamine,
penicillin/streptomycin (all from Life Technologies, Gaithersburg, MD)
and 10% FCS (Valbiotech) from day 1 with various cytokine combinations
as indicated in the text. CD1a+HLA-DR+,
CD1a+CD14-, and
CD1a-CD14+ cells were sorted with the
FACStarPlus at days 714. Monocytes were isolated from the
blood by continuous flow centrifugation leukapheresis, and counterflow
centrifugation elutriation as described (24). They were cultured in
complete RPMI 1640 as above with 50 ng/ml recombinant human GM-CSF and
200 U/ml IL-4 for 7 days.
Mixed leukocyte reaction
Variable numbers of stimulating cells from culture on day 78 or day 14 were seeded in 96-well round-bottom plates with 105 PBMC in 200 µl final volume. Random PBMC samples were obtained from our HLA-typing laboratory and used as responder cells. After 3 days of culture, 1 µCi of [3H]thymidine (sp. act., 25 Ci/mmol, Amersham) was added per well for 15 h and counted. Tests were carried in triplicates, and results are expressed as mean cpm ± SD.
Radiolabeling, biotinylation, immunoprecipitation, and electrophoresis
Cells (5 x 106) were pulse labeled with
35S Promix (Amersham) for 10 min at 37°C and chased for
various periods of time as described (25). At the indicated times,
cells were chilled in cold PBS and cell surface biotinylated with a
solution containing 25 mg of sulfosuccinimidyl-(2
biotinamide)-ethyl-1,3-dithio propionate (Pierce, Rockford, IL) in 1 ml
of cold PBS for 5 min at 4°C. The reaction was quenched with 50 mM
ice cold glycine in PBS. Cells were solubilized in 1% Triton X-100,
150 mM NaCl, 20 mM Tris-HCl, 5 mM EDTA, 0.2% BSA, and protease
inhibitors. Postnuclear lysates were precleared for 2 h with
protein A-Sepharose at 4°C. Lysates were thereafter
immunoprecipitated sequentially with Abs L243 and DA6.147 previously
bound on protein A-Sepharose CL-4B (Pharmacia, Uppsala, Sweden). This
allowed distinction between the two forms of MHC-II molecules (L243
recognizes
ß dimers while mAb DA6.147 recovers
ßIi
complexes). Immunoprecipitates were washed and eluted with 10 µl of
10% SDS at 95°C for 5 min. Eluted material was resuspended in 100
µl of lysis buffer without BSA. The efficiency of biotinylation being
1015%, biotinylated proteins were recovered with
streptavidin-agarose on 90% of the elution volume, and the remaining
10% was left untreated. Samples were boiled in Laemmlis buffer on a
1015% SDS-PAGE and run under reducing conditions (100 mM DTT).
Autoradiographies were scanned with a video camera (Bio Print System,
Vilbert Lourmat, Marne la Vallée, France).
| Results |
|---|
|
|
|---|
In previous studies, we have defined the most immature thymocyte
population as being CD34+CD1a- (19, 26). This
subset expressed CD45RA, CD38, CD7, CD2, CD5, and CD10 surface
molecules on almost all the cells and was negative for CD14 and CD33
markers (not shown). This immature subset proliferated strongly in
response to SCF + IL-7 (19) and generated
CD1a+HLA-DR+ DC when cultured in SCF + IL-7 +
flt3L+ GM-CSF + TNF-
in keeping with other results (7, 8) (Fig. 1
). As shown, only a minority of cells
matured in DC, whereas most of the cells (HLA-DR/CD1a negative (lower
left quadrant)) remained CD7+, which were IL-7-driven
prothymocytes as previously reported (19). The
CD34+1a- subset also generated a pure NK cell
population when cultured in SCF + IL-7 + flt3L + IL-2. In contrast, the
more mature CD34+1+ population was unable to
make DC and generated only low numbers of NK cells (Fig. 1
). Thus, in
liquid culture and in absence of thymic stroma,
CD34+1- could generate DC or NK cells but not
T cells even if IL-1 and IL-6 were added to the mixture (data not
shown). DC derived from thymic progenitors under SCF + IL-7 + flT3L +
GM-CSF + TNF-
localized within large cells (R1) and expressed the
following membrane Ags (Fig. 2
): HLA-DR,
CD1a, CD2, CD4, CD5, CD7, CD11b, CD11c, CD33, CD40, CD83, CD86, and
E-cadherin. In our hands, CD83 expression was low but tended to
increase at the late stage of cultures, day 14 (not shown).
Importantly, and in contrast to what has been reported for cord blood,
CD34+-derived DC (8), no CD14+ intermediates
were observed in our cultures from day 1 to day 10. Thus, thymic DC
generated in vitro shared common markers with monocyte-derived DC, such
as CD33 (28), and common markers with CD1a+-derived cord
blood DC, such as E-cadherin (8, 21).
|
|
did not appear to be indispensable for
the generation of murine (18) as well as human (20) thymic DC, we
evaluated the role of different cytokine mixtures on the growth of DC.
Table I
), the number of DC recovered was very low. Indeed, we could
generate
1.5 DC from two seeded CD34+1-
thymocytes. We found that adding TNF-
to a mixture comprising SCF +
flt3L + IL-7 + GM-CSF did not significantly enhance the number of
DC generated at day 14. This is also true when TNF-
was added to
mixtures comprising IL-3 or M-CSF.
|
Having found that DC could be generated in cultures with M-CSF we
investigated whether they passed through CD14+ intermediate
cells generated from thymic precursors. While as shown above, several
cytokines such as IL-3, M-CSF, and GM-CSF generated
HLA-DR+CD1a+ DC, only progenitors cultured with
M-CSF were able to generate CD14+ cells (Table I
). FACS
profiles (Fig. 3
A) show that
two distinct populations arose from thymic progenitors after 7 days of
culture with SCF + IL-7 + flt3L + M-CSF: a
CD1a+CD116+CD14- and a
CD1alowCD116intermediateCD14+
population. By contrast, progenitors cultured with GM-CSF led only to
the CD116+ CD14- population. Strikingly,
GM-CSF down-regulated CD116 (GM-CSF receptor) expression on
CD14- and on CD14+ cells. This cannot be
attributed to a competition between GM-CSF and the Ab for binding to
the receptor given that the CD116 mAb (see Materials and
Methods) is not blocking and recognizes the CD116-GM-CSF complex.
We observed that when progenitors were cultured for 7 days with M-CSF
and recultured for 48 h with GM-CSF, the CD14+
population disappeared and the expression of CD116 diminished, giving
the same picture as culture in GM-CSF from the start (not shown). To
determine whether CD14+ cells could generate DC,
CD14+ cells were sorted and recultured in GM-CSF or in
M-CSF alone. Within 4872 h, we observed a down-regulation of CD14 and
an up-regulation of CD1a expression with GM-CSF, whereas cells kept in
M-CSF remained CD14highCD1alow (Fig. 3
B). Cell shape was investigated by immunostaining and
confocal microscopy to determine whether our cultures generated cells
with monocytic and dendritic morphology. M-CSF-cultured cells appeared
heterogeneous in shape, some round with lobulated nuclei and others
expressing typical dendritic morphology. Cells stained weakly with CD1a
(BL6) and had surface and intracellular MHC class II molecules. The
latter colocalized in the endosomal compartment as demonstrated by
double staining with anti-MHC class II L243 and anti-LAMP
(lysosomal-associated membrane protein, CD63) H5C6 Abs (Fig. 4
). As shown by confocal microscopy, the
same cells recultured with GM-CSF (GM-CSF + M-CSF) had
homogeneous DC features with endosomal and membrane MHC class II and a
stronger CD1a expression. Thus, thymic DC differentiated directly from
CD1a+CD14- precursors under GM-CSF and
indirectly from CD1a-CD14+ cells if
sequentially cultured with M-CSF and GM-CSF.
|
|
accelerates the differentiation of progenitors into DC and
increases MHC class II membrane expression and MLR-inducing capacity of
DC
As shown in Table I
, TNF-
did not significantly increase the
number of GM-CSF-induced DC at day 14. Kinetic analysis of DC generated
from progenitors cultured in GM-CSF or GM-CSF + TNF-
showed,
however, that TNF-
accelerated the differentiation into DC (Fig. 5
), which peaked at day 810, while
culture without TNF-
peaked at day 14. TNF-
also accelerated the
differentiation into DC whether it was added to GM-CSF or to M-CSF.
Confocal microscopy studies (Fig. 6
)
showed that DC cultured with GM-CSF + TNF-
were larger and had more
class II molecules than DC cultured in GM-CSF alone. In
TNF-
-stimulated cells, MHC class II molecules localized
predominantly to the membrane, whereas they were mostly intracellular
in unstimulated cells. This is in keeping with our observations that
TNF-
-cultured DC were more active in inducing allogeneic MLR (Fig. 7
) whether TNF-
was added to M-CSF or
to GM-CSF-cultured cells. Thus, TNF-
had a dual activity. It
accelerated the differentiation of DC from thymic or cord blood
progenitors. On the other hand, it increased the capacity of DC to
induce allogeneic MLR, consistent with an increased membrane expression
of MHC class II molecules. Fig. 5
shows also that TNF-
had similar
activity on CD34+ cells from the cord blood or from the
thymus, cultured in the same conditions. However, much higher absolute
numbers (80-fold) of DC were generated from cord blood than from thymic
CD34+ precursors. This further confirmed that DC
progenitors from the cord blood or from the thymus responded in a way
similar to that of cytokines, although the latter had a very low
proliferation capacity.
|
|
|
ßIi complexes at the membrane
Thymic DC could be activated by TNF-
; this was in keeping with
microscopy findings that MHC class II was essentially expressed at the
plasma membrane in activated DC. Given the importance of intracellular
trafficking of
ß and invariant chains in the function of
monocyte-derived DC (22, 23, 27), we investigated whether thymic DC
could be differentiated from monocyte-derived DC, based on their
respective patterns of MHC class II and Ii expression and the early
steps of their intracellular trafficking (25). We have recently studied
intracellular vs membrane expression of MHC class II complexes in
monocyte-derived DC, monocytes, and EBV-transformed B cells (25).
Monocyte-derived DC synthesized a particularly high level of the p41
isoform. Most of the newly synthesized
ßIi complexes were shown to
be transported first to the plasma membrane in these cells, before
internalization of the whole complex and the generation of new
ß
dimers devoid of intact Ii chains. The same technique was applied to
the study of thymic DC, in particular to CD1a+-derived DC
using IL-7 + SCF + GM-CSF + TNF-
. However, given the paucity of
CD14+-derived DC in the thymus, especially after sorting,
we used DC derived from CD14+ blood monocytes as control.
Monocytes, blood monocyte-derived DC, and CD1a+-derived
thymic DC were pulse chase labeled and surface biotinylated at
different times. They were first immunoprecipitated with L243 mAb to
retrieve mature
ß dimers and precipitated thereafter with DA6.147
mAb to recover precursor
ßIi complexes. This method allows the
study of the kinetics of synthesis and transport and the relative
expression of both types of class II complexes. Here are shown the
autoradiography of the second immunoprecipitation step. We found that
MHC class II in thymic DC are synthesized within 30 min and that
oligomerization of
ßIi was complete within 2 h after
synthesis which was comparable in all three cell types. The main
finding was that
ßIi complexes reached the membrane of thymic DC
within 30 min1 h after their synthesis (Fig. 8
). As previously reported (25), this was
also found on myeloid DC but not on monocytes in which most of the
class II molecules remained intracellular. All Ii isoforms including
p47, the sialylated form of p41, were detected on both DC lineages, and
mature forms of Ii were transiently detected at the membrane. We could
also detect surface Ii by FACS and confocal microscopy using
supernatant from the BU 45 hybridoma as described on monocyte-derived
DC (25) (data not shown). Thus, transient membrane transit of
ßIi
complexes is a general feature of DC but not of monocytes or B-EBV
cells (25). CD1a-derived thymic DC could be differentiated from
monocytes but had no special features regarding MHC class II
trafficking as compared with CD14-derived myeloid DC.
|
| Discussion |
|---|
|
|
|---|
DC were generated from human (22) or murine (18) precursors without addition of GM-CSF. These results together with ours are likely to be due to the outgrowth of a "lymphoid" committed DC precursor under the influence of IL-7 + SCF and to a lesser extent of flt3L. Thymic precursors would mature in vitro into DC when cytokines necessary for their survival are present in the culture and provided that IL-2 (and possibly IL-15) are not added. This would avoid the outgrowth of NK cells at the expense of DC (Ref. 15 and our unpublished data). If this hypothesis is correct, the role of M-CSF in our experiments was to differentiate thymic precursors into CD14+ cells (35, 36) while sparing DC-committed precursors of lymphoid origin, which differentiated under IL-7. It could be argued that M-CSF-stimulated monocytes produced various factors including GM-CSF (37), which synergizes with M-CSF in enhancing monocyte and multipotential colony formation (38). However, it seems unlikely that "lymphoid" DC were generated through an indirect effect of M-CSF, since they were produced under IL-7 + SCF with or without GM-CSF. Finally, the addition of M-CSF to our cultures demonstrated that thymic precursors retain some monocytic differentiation capacity.
The low number of DC generated from thymic precursors is striking as
compared with the high capacity of cord blood progenitors. We were
unable to generate DC colonies in semisolid medium from
CD34+CD1a- thymocytes (not shown). This
difference may be related either to the very low number of committed DC
progenitors in the thymus or more likely to their more mature state as
compared with cord blood progenitors. Indeed the
CD34+CD1a- fraction in the thymus is
CD7high (19) and preferentially proliferates to IL-7 + SCF
(26). Their counterparts represent <10% of the cord blood
CD34+ cells with similarly low DC differentiation capacity
(our unpublished data) by contrast to the bulk CD34+
population. Thus, it is possible that thymic DC arise from bone marrow
DC directly homing into the thymus. Indeed, irradiated SCID mice
injected with bone marrow cells had their thymuses colonized with DC
before thymocyte expansion occurred (39). Alternatively, DC might be
produced in situ from CD34 precursors. This is indirectly suggested
from experiments in which
70% of CD4low thymic
precursors showed a DC differentiation capacity following in vivo
transfer to mice (5). In humans, the recently described
CD33low fraction in the thymus (15) represented 20% of
most immature CD34+1- cells used in our study.
Therefore,
0.1% of thymocytes differentiated into NK or DC,
the latter showing a 15-fold amplification from the initial progenitors
seeded. This should result in a 3-fold amplification of the
CD34+CD1a- fraction as compared with 1.5-fold
in our own hands.
We have shown the dual role of TNF-
on thymic
progenitors and on DC. Although it was not needed to generate DC, it
accelerated their maturation from CD34+ cells and activated
them as evidenced by MLR and microscopy studies. TNF-
may work
through inhibition of growth of the monocyte lineage in synergy with
GM-CSF as described (40), thereby shifting the differentiation of
CD34+ cells toward CD1a+-derived "lymphoid"
pathway. On the other hand, differentiation of DC by TNF-
and other
inflammatory stimuli such as IL-1, LPS, and bacterial products has been
demonstrated (41, 42). Following culture with TNF-
, DC up-regulate
adhesion and costimulatory molecules and no longer endocytose. As shown
here by confocal microscopy, MHC class II molecules are mostly
intracellular in immature cells while mainly located at the membrane
following stimulation with TNF-
. Our results also show that thymic
DC behave like myeloid DC, although differently from fresh monocytes,
both for the early steps of intracellular transport of
ßIi chains
and for the composition of MHC-II complexes. We have studied the
predominant thymic lymphoid DC subset (generated without M-CSF), and
compared it with blood monocyte-derived DC. We assume that the latter
is similar to the CD14+-derived thymic subset, which showed
a monocytic morphology. It has long been suggested that thymic DC had
no specific features that would explain their role in clonal deletion
of self-reactive thymocytes. Indeed they could be replaced for this
function by splenic DC (43), indirectly demonstrating that deletion is
due to the reactivity of immature thymocytes themselves, with self MHC.
Moreover, thymic DC are as good as peripheral ones in presenting Ags
(9). Altogether, we present additional arguments that although DC can
arise from different progenitors, they can be functionally very similar
provided that they are cultured in the same conditions.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Ali H. Dalloul, Laboratoire dImmunologie Cellulaire, CERVI, Hôpital Pitié-Salpêtrière, 83 Blvd de lHôpital, 75651 Paris, France. E-mail address: ![]()
3 Abbreviations used in this paper: DC, dendritic cells; M-CSF, macrophage CSF; SCF, stem cell factor. ![]()
4 B. Canque et al. Submitted for publication. ![]()
Received for publication November 18, 1998. Accepted for publication February 26, 1999.
| References |
|---|
|
|
|---|
cooperate in the generation of dendritic Langerhans cells. Nature 360:258.[Medline]
. J. Exp. Med. 184:695.
enhances the proliferative responsiveness of murine peritoneal macrophages to macrophage-colony-stimulating factor but inhibits their proliferative responsiveness to granulocyte-macrophage colony-stimulating factor. Blood 75:1627.
. J. Exp. Med. 179:1109.This article has been cited by other articles:
![]() |
E. Sejas, P. Kolsteren, T. Hoeree, and D. Roberfroid Iron Supplementation in Previously Anemic Bolivian Children Normalized Hematologic Parameters, But Not Immunologic Parameters J Trop Pediatr, June 1, 2008; 54(3): 164 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Haddad, P. Guardiola, B. Izac, C. Thibault, J. Radich, A.-L. Delezoide, C. Baillou, F. M. Lemoine, J. C. Gluckman, F. Pflumio, et al. Molecular characterization of early human T/NK and B-lymphoid progenitor cells in umbilical cord blood Blood, December 15, 2004; 104(13): 3918 - 3926. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Okamoto, D. C. Douek, R. D. McFarland, and R. A. Koup Effects of exogenous interleukin-7 on human thymus function Blood, April 15, 2002; 99(8): 2851 - 2858. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. G. de Yebenes, Y. R. Carrasco, A. R. Ramiro, and M. L. Toribio Identification of a myeloid intrathymic pathway of dendritic cell development marked by expression of the granulocyte macrophage-colony-stimulating factor receptor Blood, April 15, 2002; 99(8): 2948 - 2956. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Vandenabeele, H. Hochrein, N. Mavaddat, K. Winkel, and K. Shortman Human thymus contains 2 distinct dendritic cell populations Blood, March 15, 2001; 97(6): 1733 - 1741. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Spits, F. Couwenberg, A. Q. Bakker, K. Weijer, and C. H. Uittenbogaart Id2 and Id3 Inhibit Development of CD34+ Stem Cells into Predendritic Cell (Pre-DC)2 but Not into Pre-DC1: Evidence for a Lymphoid Origin of Pre-DC2 J. Exp. Med., December 18, 2000; 192(12): 1775 - 1784. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schmitt, H. Fohrer, S. Beaudet, P. Palmer, M.-J. Alpha, B. Canque, J. C. Gluckman, and A. H. Dalloul Identification of mature and immature human thymic dendritic cells that differentially express HLA-DR and interleukin-3 receptor in vivo J. Leukoc. Biol., December 1, 2000; 68(6): 836 - 844. [Abstract] [Full Text] |
||||
![]() |
B. Canque, S. Camus, A. Dalloul, E. Kahn, M. Yagello, C. Dezutter-Dambuyant, D. Schmitt, C. Schmitt, and J. C. Gluckman Characterization of dendritic cell differentiation pathways from cord blood CD34+CD7+CD45RA+ hematopoietic progenitor cells Blood, December 1, 2000; 96(12): 3748 - 3756. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||